MAP2K7 and non-small cell lung carcinoma: In non-small cell lung cancer, kras mutations result in activation of the RAF/MEK/ERK pathway, where by inhibition of MEK with a MEK inhibitor is ineffective because of alternative activation of the PI3CK/AKT/mTOR pathway (121).